CommercialCoverageHigh impact
Medical Policy Updates August 5, 2026
Blue Cross NC·NC · Allergy & Immunology, Cardiology, Internal Medicine +5 more·Medical Policy
Effective date
Aug 5, 2026
We identified it
Aug 6, 2026
Summary
Blue Cross NC issued a comprehensive medical policy update effective August 5, 2026, affecting 11 clinical policies including allergen testing, cardiovascular risk assessment, sexually transmitted infection testing, and colorectal cancer screening. Multiple billing codes were added, removed, or modified across these policies, requiring immediate system updates and billing team training to ensure accurate claim submission and avoid denials.
Action Required
By August 5, 2026: (1) ALLERGEN TESTING: Billing team must add CPT 95004 to system and update coverage to limit reimbursement to 40 allergen-specific antibodies per year. New rule: deny claims for specific IgE testing performed same day as skin prick testing (add edits to billing system). (2) CARDIOVASCULAR RISK ASSESSMENT: Update system to add CPT 83876; modify coverage to expand screening age criteria (remove age 18 restriction); change frequency from every 4 years to every 5 years for standard risk; change CC1 c) iii) to allow testing every 3-12 months (not annually) for high-risk patients; add code restriction (no more than once every 4 weeks) to CC2; remove CRP testing and add myeloperoxidase to non-covered codes. (3) STI TESTING (AHS-G2157): Remove CPT codes 86704, 86706, 87340, G0499 from system; add CPT codes 87140, 87270, 87285, 87320, 87660, 87810. Update coverage rules: integrate prenatal STI screening into this policy; require 3-month minimum for gonorrhea test-of-cure (TOC); deny treponemal testing for patients with current or past syphilis diagnosis; deny PCR, NAAT, and antigen testing for syphilis; deny culture, antibody, and antigen testing for chlamydia/LGV; add Trichomonas vaginalis coverage under this policy (moved from vaginitis policy). (4) VAGINITIS TESTING (M2057): Remove CPT 87660 from individual testing coverage; require multi-pathogen panel testing for Trichomonas (deny individual Trichomonas testing); update Candida testing requirement to NAAT (nucleic acid amplification testing), not direct probe. (5) ESOPHAGEAL PATHOLOGY: Remove CPT codes 88112, 88160, 88305, 88312; update coverage to include repotrectinib therapy indication; update genetic testing to specify NTRK1/2/3 gene fusion; replace BarreGEN test with TissueCypher® Barrett's Esophagus Assay in non-covered section. (6) COLORECTAL CANCER SCREENING: Archive old policy B0001 and implement new policy AHS-G2181 with integrated criteria; verify coverage criteria are loaded in system. (7) All billing software rules must be updated by affected date; providers must be notified of coverage/non-coverage changes via EMR updates and encounter form changes to prevent inappropriate billing. Failure to comply will result in claim denials and potential recoupment.